Glioblastoma in the post-2021 era: Diagnostic recalibration, therapeutic innovations, and future horizons
World Journal of Clinical Oncology · 24.06.2026 · 17 (6)
DOI: 10.5306/wjco.118209 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Clinical Oncology, online erschienen am 24.06.2026. Verfasst von Sagar Raut und 2 weiteren Autor:innen. Die Arbeit nennt 99 Literaturangaben.
Abstract (Originalsprache)
Glioblastoma (GBM) remains a devastating diagnosis, and since 2021, the field has witnessed both incremental advances and renewed paradigms in diagnosis, therapeutic development, and trial design. The 2021 WHO Central Nervous System 5 classification redefined GBM as isocitrate dehydrogenase (IDH)-wildtype, sharpening the molecular underpinnings of clinical trial cohorts. Targeted approaches in selected molecular subsets (e.g., IDH inhibitors) have matured, while tumor-treating fields remains a debated but utilised adjunct. Immunotherapy via checkpoint inhibitors has been disappointing in unselected populations, but newer vaccines, oncolytic viral, and combination strategies are under active development. The most hopeful advances in the 2023-2025 window come from engineered cell therapies, especially chimeric antigen receptor T-cell delivered locoregionally or with multivalent antigen specificity. Advances in liquid biopsy, spatial transcriptomics, imaging biomarkers, and adaptive trial platforms are converging to accelerate translation. This narrative review synthesises developments since 2021, integrating translational insight and practical guidance, and outlines a roadmap for the next decade of GBM research.
Zitieren
APA
Raut, S., Samala, S. K., & Prusty, S. K. (2026). Glioblastoma in the post-2021 era: Diagnostic recalibration, therapeutic innovations, and future horizons. World Journal of Clinical Oncology, 17(6). https://doi.org/10.5306/wjco.118209
Vancouver
Raut S, Samala SK, Prusty SK. Glioblastoma in the post-2021 era: Diagnostic recalibration, therapeutic innovations, and future horizons. World Journal of Clinical Oncology. 2026;17(6). doi:10.5306/wjco.118209
BibTeX
@article{Raut2026,
author = {Raut, Sagar and Samala, Sai Kumar and Prusty, Santosh K},
title = {Glioblastoma in the post-2021 era: Diagnostic recalibration, therapeutic innovations, and future horizons},
journal = {World Journal of Clinical Oncology},
year = {2026},
volume = {17},
number = {6},
doi = {10.5306/wjco.118209}
}
EUVIMED